Anthem (Elevance Health) Mavyret Prior Authorization: A Strategic Approach
Streamlining **Anthem (Elevance Health) Mavyret prior authorization** is critical for ensuring timely patient access to this essential Hepatitis C treatment while optimizing revenue cycles.
For revenue cycle directors and prior authorization coordinators, managing high-volume specialty drug PAs like Mavyret requires deep insight into payer-specific workflows and clinical criteria. Klivira provides a robust solution to automate these complex interactions, bridging the gap between EMRs and payer portals.
Understanding Mavyret's PA Landscape with Anthem (Elevance Health)
Mavyret (glecaprevir/pibrentasvir) is a direct-acting antiviral indicated for chronic Hepatitis C virus (HCV) infection, representing a high-cost, high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans. Its therapeutic impact necessitates efficient PA processes to ensure patients receive timely access to this critical medication.
Navigating Anthem's Mavyret Prior Authorization Channels
For Anthem-licensed plans, Mavyret prior authorizations typically route through the pharmacy benefit, managed by CarelonRx (Elevance Health's in-house PBM). Prescriber-initiated ePA submissions are facilitated via industry partners like CoverMyMeds and Surescripts. While primarily a pharmacy benefit drug, any medical benefit administration would utilize Availity Essentials for submission or X12 278 transactions via clearinghouses.
Key Policy and Clinical Criteria for Mavyret
Anthem operating companies publish medical-policy and clinical-UM-guideline libraries through provider sites accessed via Availity. For Mavyret, these policies will outline medical necessity criteria, often including specific genotype, liver disease stage, and prior treatment history. Common requirements may also include step therapy protocols or quantity limits, which must be verified against the specific state-plan formulary and policy.
Anticipating Mavyret Prior Authorization Denials from Anthem
Common denial categories for Mavyret PAs from Anthem include insufficient documentation of medical necessity, failure to complete required step therapy, or non-formulary status for the specific state plan. Denials are typically communicated via X12 277/835 transactions or through Availity status updates, necessitating a clear understanding of the specific rationale for efficient resolution.
Expediting Mavyret PA Decisions and Appeals
Prior authorization turnaround times for Anthem-licensed plans are governed by state-specific regulations for commercial lines, while Medicare Advantage and Medicaid managed-care plans are subject to CMS-0057-F decision timeframes (72-hour standard, 24-hour expedited). Should a Mavyret PA be denied, appeals route through the Anthem operating-company appeals process, with peer-to-peer reviews available to address clinical rationale.
Frequently asked questions
How are Mavyret prior authorizations typically submitted to Anthem (Elevance Health)?
Mavyret PAs for Anthem-licensed plans primarily route through the pharmacy benefit, managed by CarelonRx. Submissions can be initiated electronically via ePA partners like CoverMyMeds and Surescripts. For any medical benefit scenarios, Availity Essentials or X12 278 transactions would be the primary channels.
Where can I find Anthem's clinical criteria for Mavyret?
Anthem operating companies publish their medical policies and clinical utilization management guidelines on provider sites, accessible through Availity. It is crucial to consult the specific policy number, plan-state context, and effective date to ensure compliance with the most current Mavyret criteria.
What are common reasons Anthem denies Mavyret prior authorizations?
Frequent denial reasons for Mavyret PAs from Anthem include insufficient documentation to prove medical necessity, failure to adhere to specific step therapy requirements, or if the drug is deemed non-formulary for the member's specific plan. Site-of-service mismatch can also be a factor for certain specialty drugs.
Does CMS-0057-F apply to Mavyret PAs with Anthem?
Yes, Anthem's Medicare Advantage and Medicaid managed-care plans (including Wellpoint subsidiary brands) are impacted payers under CMS-0057-F. This rule mandates specific PA decision timeframes, including 72 hours for standard requests and 24 hours for expedited requests, which apply to Mavyret PAs under these plans.
What is the appeal process for a denied Mavyret PA from Anthem?
For a denied Mavyret prior authorization, appeals route through the standard Anthem operating-company appeals process, as detailed in the provider manual. This typically involves submitting additional clinical documentation, and a peer-to-peer review with an Anthem medical director is often available to discuss the clinical rationale.
Related coverage
Other mavyret prior authorization by payer
- Navigating Aetna Mavyret Prior Authorization for Efficient Approvals
- Navigating Cigna Mavyret Prior Authorization for Hepatitis C Treatment
- Streamlining Humana Mavyret Prior Authorization Workflows
- Streamlining Medicaid Mavyret Prior Authorization Workflows
- Streamlining Medicare Mavyret Prior Authorization Workflows
- Streamlining UnitedHealthcare Mavyret Prior Authorization
Other mavyret prior authorization by specialty
- Optimizing Mavyret Prior Authorization for Cardiology Patient Populations
- Mavyret Prior Authorization for Endocrinology: Optimizing Workflow
- Streamlining Mavyret Prior Authorization for Gastroenterology
- Streamlining Mavyret Prior Authorization for Oncology Patients
- Mavyret Prior Authorization for Orthopedics: Streamlining Co-managed Patient Care
Ready to automate prior auth for this drug?
See how Klivira automates prior authorizations for your team.
Request a demo